Physician

Internal Medicine

Ivan M. Lieberburg, MD practices Internal Medicine. He has 4 awards "Kaiser Teaching Award", "Neuroscience Fellow", "Scholar" and "National Research Service Awardee". Dr. Ivan M. Lieberburg is a published doctor as well. He has 40 publications published. The latest was: High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

Publications

---

• Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.
• Lethality of Alzheimer disease and its impact on nursing home placement.
• A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.
• Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.
• beta-peptide immunization: a possible new treatment for Alzheimer disease.
• Purification and cloning of amyloid precursor protein beta-secretase from human brain.
• Cellular mechanisms of beta-amyloid production and secretion.
• Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.
• High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
• Estrogen therapy in postmenopausal women: effects on cognitive function and dementia.
• Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease.
• The regulatory Ser262 of microtubule-associated protein tau is phosphorylated by phosphorylase kinase.
• The effect of apolipoprotein E genotype on biochemical markers of Alzheimer's disease.
• Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice.
• Beta-secretase processing of the beta-amyloid precursor protein in transgenic mice is efficient in neurons but inefficient in astrocytes.
• Production and increased detection of amyloid beta protein and amyloidogenic fragments in brain microvessels, meningeal vessels and choroid plexus in Alzheimer's disease.
• Amyloid beta-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation.
• Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease.
• Therapeutic approaches related to amyloid-beta peptide and Alzheimer's disease.
• Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau.
• Chronic elevation of secreted amyloid precursor protein in subcortically lesioned rats, and its exacerbation in aged rats.
• Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease.
• Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype.
• Future directions for research on Alzheimer's disease.
• Channel formation in planar lipid bilayers by a neurotoxic fragment of the beta-amyloid peptide.
• Identification of secreted beta-amyloid precursor protein binding sites on intact human fibroblasts.
• Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro.
• Regulated cleavage of Alzheimer beta-amyloid precursor protein in the absence of the cytoplasmic tail.
• Serine phosphorylation of the secreted extracellular domain of APP.
• beta-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease.
• Cells with a familial Alzheimer's disease mutation produce authentic beta-peptide.
• Characterization of beta-amyloid peptide from human cerebrospinal fluid.
• Altered calcium signaling and neuronal injury: stroke and Alzheimer's disease as examples.
• Development of lipophilic anticancer agents for the treatment of brain tumors by the esterification of water-soluble chlorambucil.
• Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein.
• Microinjection of synthetic amyloid beta-protein in monkey cerebral cortex fails to produce acute neurotoxicity.
• Mutation of the beta-amyloid precursor protein in familial Alzheimer''s disease increases beta-protein production.
• Beta/A4 domain of APP: antigenic differences between cell lines.
• Amyloid beta-peptide is produced by cultured cells during normal metabolism.

Schools

---

• University of Miami School of Medicine

• University Calif Hospital

Doctors Specialties

---

• Internal Medicine

Accepted Insurances

---

• Aetna
• Medicare MCR

Awards

---

• Kaiser Teaching Award
• Neuroscience Fellow
• Scholar
• National Research Service Awardee

Education

---

• UCSF
• Cornell University

Hospital

---

• San Francisco VA Medical Center

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Robert S. Yuhas, MD This Doctor is OpenDoctor Recommended.
	Dr. Mark E. Kalina, MD This Doctor is OpenDoctor Recommended.
	Dr. Michael J. Sullivan, MD
	Dr. Lawrence I. Susnow, MD This Doctor is OpenDoctor Recommended.
	Dr. Daniel M. Pertschuk, MD
	Dr. William D. Rawlings, DDS This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog